Compare Amphastar Pharmaceuticals Inc (AMPH) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while YieldMax NVDA Option Income Strategy ETF trades at $12.63. Which is the better fit depends on your goals.
| AMPH | NVDY | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $30.81 | $17.96 |
52-Week Low | $16.87 | $12.03 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.75, up 2.66% today, amid a bearish technical signal. The fund generates weekly dividends from selling options on NVIDIA stock, with recent payouts ranging from $0.10 to $0.21. Key support sits at $12, resistance at $13, while RSI readings are neutral but ADX indicates a strong downtrend. News highlights focus on the trade-off between income and missing NVIDIA's upside potential.
Outlook hinges on NVIDIA's volatility sustaining option premiums, offering high yield but capped gains. Risks include underperformance if NVIDIA rallies sharply and reliance on options strategy execution. The fund appeals to income-focused investors willing to sacrifice growth for distributions, with sentiment mixed due to opportunity cost concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
